[ad_1]
Dr. Nader Pourhbadan, CEO of CytoDyn Inc. (OTCMKTS: CYDY), told Proactive Investors that the advanced-stage biotechnology company was calling on Dr. Jonah Sacha, a veteran of the industry, as the company's chief scientific advisor .
According to Dr. Pourhbadan, Dr. Sacha, who does not own an equity stake in the company, will lead the development of the company's flagship drug, leronlimab (PRO 140), as a potential treatment for pre-exposure prophylaxis. HIV and HIV treatment.
Source link
